Organization | Canadian Cancer Society

Canadian Cancer Society Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Toronto ON Canada (1938)

Organization Overview

First Clinical Trial

2008

NCT00741364

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Canadian Cancer Society (CCS) | Canadian Cancer Society Research Institute (CCSRI)

Active Ingredients

Drugs in Phase 4 Trials (1)

nicotine (nicorette) (3 trials)

Drugs in Phase 3 Trials (3)

cefazolin (ancef) (1 trial)

eplerenone (inspra) (1 trial)

Inactivated Mycobacterium obuense (1 trial)

Drugs in Phase 2 Trials (9)

acetylsalicylic acid (aspirin) (1 trial)

cannabis (1 trial)

cord blood expanded with um171 (1 trial)

gemcitabine (gemzar) (1 trial)

slc-0111 (1 trial)

sunitinib (sutent) (1 trial)

tamoxifen (nolvadex) (1 trial)

temozolomide (temodar) (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Bone Neoplasms (Phase 3)

Breast Neoplasms (Phase 3)

Glioblastoma (Phase 2)

Infections (Phase 3)

Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Tobacco Use Disorder (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 13
# of Trial APIs: 13